Clinical Trials
12 trialsNCT06551324 2026-05-05
MEVPRO-1
Pfizer
Phase 3 Active not recruiting
NCT05126719 2026-02-06
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
Shanghai Miracogen Inc.
Phase 2 Active not recruiting
NCT06976190 2026-01-20
Magic-C002
Shanghai Miracogen Inc.
Phase 3 Recruiting
NCT06892431 2025-03-25
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
Shanghai JMT-Bio Inc.
Phase 2 Not yet recruiting
NCT06525350 2024-07-29
A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel(Albumin Bound)Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Not yet recruiting
NCT02460367 2022-04-06
Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
Lumos Pharma
Phase 1 Terminated
NCT01774578 2020-05-28
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Lumos Pharma
Phase 2/3 Terminated
NCT02322281 2019-08-14
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
Clovis Oncology, Inc.
Phase 3 Terminated
NCT02346370 2019-02-08
PRIMAL
Halozyme Therapeutics
Phase 1 Terminated
NCT00454779 2018-10-17
PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response
Amgen
Phase 2 Completed
NCT00095199 2012-10-15
Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 3 Completed
NCT00356122 2011-10-17
Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Sanofi
Phase 2 Completed